Merck, C1163-1ML, Complement C5 deficient serum human

Application
Complement C5 deficiencies in humans are rare, but often associated with recurrent infections by Neisseria spp. (such as meningitis). Deficiency in C5 results in an impairment of hemolytic activity from both the classical and alternative pathway of the complement system. Recently, genetic research has revealed that a 153 bp deletion in exon 30 results in complete C5 deficiency. Research has also implicated C5 deficiency in a predisposition to cardiac dysfunction when cardiac injury occurs.
Biochem/physiol Actions
Complement C5 deficiency can, paradoxically, protect against certain effects of infection. Patients deficient in C5 are unusually susceptible to meningococcal infection, but have a milder course of infection. Reduced expression of tumor necrosis factor (TNF) may account for this effect.
Physical form
Supplied as a solution in PBS, pH 7.4
Analysis Note
C5 is depleted by immunoadsorption as determined by hemolytic assay.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.